false
0001676163
FL
IN
0001676163
2026-11-19
2026-11-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): November 19, 2026
SS INNOVATIONS INTERNATIONAL, INC.
(Exact
name of registrant as specified in its charter)
| Florida |
|
001-42615 |
|
47-3478854 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification
No.) |
405, 3rd Floor, iLabs Info Technology Centre
Udyog Vihar, Phase III
Gurugram,
Haryana India |
|
122016 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: +91 73375 53469
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common Stock |
|
SSII |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As
used in this Current Report on Form 8-K (this “Current Report”), the terms “SSi,” “the
Company,” “we,” “us” and “our” refer to SS Innovations International,
Inc. and its subsidiaries.
Item
8.01 Other Events.
On
November 19, 2026, SSi issued a press release announcing that a team of surgeons successfully completed the world’s first
dual-console, beating-heart Totally Endoscopic Coronary Artery Bypass (“TECAB”) surgery utilizing all five arms
of the Company’s SSi Mantra surgical robotic system at Medanta - The Medicity Hospital in Gurugram, India.
A
copy of the press release is included as Exhibit 99.1 to this Current Report.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release, dated November 19, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Dated:
November 19, 2026 |
SS
INNOVATIONS INTERNATIONAL, INC. |
| |
|
|
| |
By: |
/s/
Sudhir Srivastava |
| |
|
Sudhir
Srivastava, M.D. |
| |
|
Chairman
and Chief Executive Officer |
Exhibit
99.1

SS Innovations Announces World’s First
Dual-Console, Beating-Heart TECAB Surgery Utilizing
All Five Arms of the SSi Mantra Surgical Robotic System
Landmark
procedure successfully performed at Medanta Hospital in Gurugram, India, demonstrating the power of dual-console technology in complex
robotic cardiac surgeries
FORT
LAUDERDALE, Fla. – November 19, 2026 –
SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII),
a developer of innovative surgical robotic technologies dedicated to
making robotic surgery affordable and accessible to a global population, today announced that a team of surgeons successfully completed
the world’s first dual-console, beating-heart Totally Endoscopic Coronary Artery Bypass (“TECAB”) surgery utilizing
all five arms of the Company’s SSi Mantra surgical robotic system (the “SSi Mantra”) at Medanta - The Medicity
Hospital (“Medanta Hospital”) in Gurugram, India.
| Dr. Nitin Kumar Rajput of Medanta Hospital and Dr. Lalit Malik of Manipal Hospital, Jaipur, successfully performed the beating-heart TECAB
procedure using two separate consoles and the SSi Mantra, under the guidance of Dr. Sudhir Srivastava, the Company’s Chairman of
the Board and Chief Executive Officer. The two surgeons completed the complex cardiac procedure using all five of the SSi Mantra’s
arms simultaneously, in complete synchronization, under a dual-console configuration. A heart stabilization system steadied the target
area while the patient’s heart continued to beat. |
|
 (Dr. Rajput and Dr. Malik performing the world's first dual-console,
beating-heart TECAB surgery utilizing all five arms of the SSi Mantra at Medanta Hospital in Gurugrum, India) |
TECAB
surgery is a highly complex form of a coronary artery bypass procedure performed through small incisions, without opening the chest,
unlike a conventional sternotomy. The beating-heart approach allows surgeons to perform the bypass while the heart continues to beat,
without using a heart-lung machine. Combining this technique with a five-arm robotic configuration under dual-console control marks a
significant advancement in the application of robotics to minimally invasive cardiac surgery.
For
video highlights of the dual-console, beating-heart TECAB surgery, please visit: link.
Dr.
Srivastava commented, “The successful use of dual-console control and five robotic arms in a beating-heart TECAB procedure
demonstrates the advanced capabilities of the SSi Mantra in enabling complex minimally invasive cardiac surgeries. Our mission at SS
Innovations is to democratize access to world-class robotic surgery, including the most intricate cardiac procedures, and this achievement
brings us a step closer to that goal.”
Dr.
Naresh Trehan, Chairman and Managing Director of Medanta Hospital, said, “I am delighted to share with you that we have
performed the first coronary bypass surgery using the SSi Mantra robot where we have used five arms and a dual console. This is the first
time that this has been done in the world, and the patient is doing extremely well. The robot, and the whole procedure went marvelously,
and everything went according to schedule. I believe that this innovation by Dr. Sudhir Srivastava and his team at SS Innovations has
really transformed the way we will do robotic surgery in the future. Today is a landmark day from our point of view.”
Dr.
Rajput said, “Performing a complex beating-heart bypass procedure using five robotic arms and two control consoles requires
precision, coordination and close collaboration between the surgeons. This approach allowed us to work in synchronization throughout
the procedure. The patient’s recovery following surgery was encouraging and reinforces the potential of minimally invasive robotic
techniques in advancing cardiac care.”
Dr.
Malik added, “This procedure marks an important step in the evolution of robotic cardiac surgery. The dual-console setup
enabled coordinated control between the two surgeons, while the five-arm configuration supported the technical demands of the operation.
Such advancements can help expand the possibilities of minimally invasive cardiac procedures and improve the overall surgical experience
for patients.”
For
a video message from Dr. Srivastava, please visit: link.
For
a video message from Dr. Trehan, please visit: link.
About
SS Innovations
SS
Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of
robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its
proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments,
which support a variety of surgical robotic procedures, including cardiac surgery. Headquartered in India, SS Innovations is a U.S. company
focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
About
the SSi Mantra
The
SSi Mantra surgical robotic system is a modular, multi-arm system with advanced technology features, including 3 to 5 modular robotic
arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch-panel monitor for displaying all patient-related
information, a virtual real-time image of the robotic patient-side arm carts, and the ability to superimpose 3D models of diagnostic
imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon
command center that is intended to provide equivalent control functionality while enabling enhanced portability, ergonomic flexibility,
and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different
specialties, including cardiac surgery, and 5 mm instruments for the pediatric population and ENT surgeries. A vision cart is designed
to provide the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra
has been clinically validated in India in more than 190 different types of surgical procedures.
Forward-Looking
Statements
This
press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private
Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,”
“expect,” “will,” “intend,” “may,” “plan,” “project,” “should,”
“could,” “seek,” “designed,” “potential,” “forecast,” “target,”
“objective,” “goal,” or the negatives of such terms or other similar expressions identify such forward-looking
statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially
different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor
Contact:
The
Equity Group
Kalle
Ahl, CFA
T:
(303) 953-9878
kalle.ahl@theequitygroup.com
Devin
Sullivan, Managing Director
T:
(212) 836-9608
devin.sullivan@theequitygroup.com
Media
Contact:
RooneyPartners
LLC
Kate
Barrette
T:
(212) 223-0561
kbarrette@rooneypartners.com